The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | Unmet needs in DLBCL: frontline therapy, CAR-T optimization, and clinical trial inclusion
Grzegorz Nowakoski, MD, Mayo Clinic, Rochester, MN, discusses three main unmet needs in diffuse large B-cell lymphoma (DLBCL): frontline therapy options, CAR T-cell therapy optimization, and incorporating elderly patients with comorbidities into trials. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: MorphoSys, Celgene/Bristol Myers Squibb, Roche, Genentech, Kyte Pharma, Ryvu Therapeutics, Selvita, Curis, Karyopharm Therapeutics, Bantham Pharmaceutical, Daiichi Sankyo, Zai Labolatory, Incyte, Kymera Therapeutics, TG Therapeutics, Blueprint Medicines
